Julian Yeoh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Julian Yeoh has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Omar Farouque
The University of Melbourne Clinical School, Austin Health, Department of Cardiology, Melbourne, Victoria, Australia
7 shared publications - Garry W. Hamilton
Department of Cardiology, Austin Health, Melbourne, VIC 3084, Australia
5 shared publications - Matias B. Yudi
Department of Cardiology, The University of Melbourne Clinical School, Austin Health, Melbourne, Victoria, Australia
5 shared publications - Anoop Ninan Koshy
The University of Melbourne Clinical School, Austin Health, Department of Cardiology, Melbourne, Victoria, Australia
4 shared publications Rafal Dworakowski
King’s College Hospital NHS Foundation Trust, London, United Kingdom (M.A.R., M.M.G., S.M.G., R.D., A.M.S., P.M.C., J.B., N.P.).
4 shared publications- Ali Al-Fiadh
Department of Cardiology, Austin Health, Heidelberg, VIC, Australia
3 shared publications
Latest Publications
- Open Access
- 15 May 2026
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 35 (6) , 821-831
Quality of Life and Function After TAVI in Adults Aged ≥90 Years: Frailty and Multimorbidity Matter
- 15 May 2026
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 35 (6) , 821-831
Open AccessQuality of Life and Function After TAVI in Adults Aged ≥90 Years: Frailty and Multimorbidity Matter
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (4) , e015918
Prospective Validation of the MIRACLE 2 Score for Early Neurological Stratification After Out-of-Hospital Cardiac-Arrest: The GLOBAL-MIRACLE Registry
BACKGROUND: The purpose of this study was to prospectively validate the MIRACLE 2 score in the GLOBAL-MIRACLE registry, a multicenter, international, prospective registry of patients admitted with resuscitated out-of-hospital cardiac arrest of presumed cardiac cause. METHODS: From January 1, 2022 to May 31, 2023, 770 patients were recruited from 11 centers across 5 countries. The primary end point was poor neurological outcome (Cerebral Performance Category 3–5) at hospital discharge. Model discrimination was assessed by the area under the receiver operating characteristic curve. We compared the discriminatory performance of the MIRACLE 2 score against Cardiac Arrest Hospital Prognosis, out-of-hospital cardiac arrest, Target Temperature Management, NULL-PLEASE, C-GRAPH, and rCAST. RESULTS: The primary end point occurred in 395 (51.2%) patients. The MIRACLE 2 score had an area under the curve of 0.861 (95% CI, 0.835–0.887). A MIRACLE 2 score ≤2 had a negative predictive value of 87.8%, while a score of ≥7 had a positive predictive value of 98.3%. The MIRACLE 2 score had equal performance to the TTM risk tool ( P =0.12) but better discriminatory performance than other risk tools ( P 2 score showed good performance in those with ST-segment–elevation myocardial infarction (0.851 [95% CI, 0.816–0.886]) and without ST-segment–elevation myocardial infarction (0.873 [95% CI, 0.834–0.912]) and in those with cardiogenic shock (0.832 [95% CI, 0.789–0.875]) and without cardiogenic shock (0.853 [95% CI, 0.810–0.895]). CONCLUSIONS: The MIRACLE 2 score is a practical risk tool that shows excellent discrimination performance for poor neurological outcome after presumed cardiac cause out-of-hospital cardiac arrest, including based on hemodynamic status and admission 12-lead ECG. Early stratification of out-of-hospital cardiac arrest patients using the MIRACLE 2 score should be evaluated in future randomized controlled trials.
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (4) , e015918
Prospective Validation of the MIRACLE 2 Score for Early Neurological Stratification After Out-of-Hospital Cardiac-Arrest: The GLOBAL-MIRACLE Registry
BACKGROUND: The purpose of this study was to prospectively validate the MIRACLE 2 score in the GLOBAL-MIRACLE registry, a multicenter, international, prospective registry of patients admitted with resuscitated out-of-hospital cardiac arrest of presumed cardiac cause. METHODS: From January 1, 2022 to May 31, 2023, 770 patients were recruited from 11 centers across 5 countries. The primary end point was poor neurological outcome (Cerebral Performance Category 3–5) at hospital discharge. Model discrimination was assessed by the area under the receiver operating characteristic curve. We compared the discriminatory performance of the MIRACLE 2 score against Cardiac Arrest Hospital Prognosis, out-of-hospital cardiac arrest, Target Temperature Management, NULL-PLEASE, C-GRAPH, and rCAST. RESULTS: The primary end point occurred in 395 (51.2%) patients. The MIRACLE 2 score had an area under the curve of 0.861 (95% CI, 0.835–0.887). A MIRACLE 2 score ≤2 had a negative predictive value of 87.8%, while a score of ≥7 had a positive predictive value of 98.3%. The MIRACLE 2 score had equal performance to the TTM risk tool ( P =0.12) but better discriminatory performance than other risk tools ( P 2 score showed good performance in those with ST-segment–elevation myocardial infarction (0.851 [95% CI, 0.816–0.886]) and without ST-segment–elevation myocardial infarction (0.873 [95% CI, 0.834–0.912]) and in those with cardiogenic shock (0.832 [95% CI, 0.789–0.875]) and without cardiogenic shock (0.853 [95% CI, 0.810–0.895]). CONCLUSIONS: The MIRACLE 2 score is a practical risk tool that shows excellent discrimination performance for poor neurological outcome after presumed cardiac cause out-of-hospital cardiac arrest, including based on hemodynamic status and admission 12-lead ECG. Early stratification of out-of-hospital cardiac arrest patients using the MIRACLE 2 score should be evaluated in future randomized controlled trials.
- Open Access
- 3 June 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (12) , 1522-1532
Abdominal aortic calcification on routine preoperative computed tomography—A novel cardiovascular risk prediction tool in liver transplant patients
Cardiovascular (CV) disease is a leading cause of postoperative mortality following liver transplantation (LT). The presence of abdominal aortic calcification (AAC) has been linked to CV events in the general population. We sought to investigate whether AAC on routine pre-transplant CT can improve the prediction of coronary artery disease, post-LT major adverse cardiovascular events (MACEs) or long-term mortality. Of 461 patients undergoing LT between 2010 and 2018, 318 were included in the analysis, among whom 81 had also undergone computed tomography coronary angiography. The extent of AAC was quantified with high AAC defined as a calcium score ≥500. High AAC was identified in 84/318 (26.4%) and demonstrated moderate correlation with coronary artery calcium score (CACS) ( r =0.52, p p =0.02). It was also associated with a significantly increased risk of 30-day MACE (OR 2.34, 95% CI 1.08–5.05, p =0.03) and long-term mortality (HR 2.45, 95% CI 1.18–5.06, p =0.02). Following multivariate analysis adjusting for pertinent CV risk factors, high AAC remained a strong independent predictor of MACE (OR 3.10, 95% CI 1.27–7.60, p =0.02). Addition of AAC to the Revised Cardiac Risk Index significantly improved model fit for predicting MACE outcomes ( p <0.01), while the absence of heavy AAC ruled out moderate-to-severe disease on CT coronary angiography with a negative predictive value of 97.0%. High AAC on routine CT scans was associated with a 3-fold increased risk of 30-day MACE post-LT and improved CV risk prediction compared to traditional indices. Quantification of AAC may offer a simple method of improving CV risk assessment in these patients.
- 3 June 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (12) , 1522-1532
Open AccessAbdominal aortic calcification on routine preoperative computed tomography—A novel cardiovascular risk prediction tool in liver transplant patients
Cardiovascular (CV) disease is a leading cause of postoperative mortality following liver transplantation (LT). The presence of abdominal aortic calcification (AAC) has been linked to CV events in the general population. We sought to investigate whether AAC on routine pre-transplant CT can improve the prediction of coronary artery disease, post-LT major adverse cardiovascular events (MACEs) or long-term mortality. Of 461 patients undergoing LT between 2010 and 2018, 318 were included in the analysis, among whom 81 had also undergone computed tomography coronary angiography. The extent of AAC was quantified with high AAC defined as a calcium score ≥500. High AAC was identified in 84/318 (26.4%) and demonstrated moderate correlation with coronary artery calcium score (CACS) ( r =0.52, p p =0.02). It was also associated with a significantly increased risk of 30-day MACE (OR 2.34, 95% CI 1.08–5.05, p =0.03) and long-term mortality (HR 2.45, 95% CI 1.18–5.06, p =0.02). Following multivariate analysis adjusting for pertinent CV risk factors, high AAC remained a strong independent predictor of MACE (OR 3.10, 95% CI 1.27–7.60, p =0.02). Addition of AAC to the Revised Cardiac Risk Index significantly improved model fit for predicting MACE outcomes ( p <0.01), while the absence of heavy AAC ruled out moderate-to-severe disease on CT coronary angiography with a negative predictive value of 97.0%. High AAC on routine CT scans was associated with a 3-fold increased risk of 30-day MACE post-LT and improved CV risk prediction compared to traditional indices. Quantification of AAC may offer a simple method of improving CV risk assessment in these patients.
- Open Access
- 28 July 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (15) , 4416
Management of Acute Coronary Syndromes in Older People: Comprehensive Review and Multidisciplinary Practice-Based Recommendations
Managing health care for older adults aged 75 years and older can pose unique challenges stemming from age-related physiological differences and comorbidities, along with elevated risk of delirium, frailty, disability, and polypharmacy. This review is aimed at providing a comprehensive analysis of the management of acute coronary syndromes (ACS) in older patients, a demographic substantially underrepresented in major clinical trials. Because older patients often exhibit atypical ACS symptoms, a nuanced diagnostic and risk stratification approach is necessary. We aim to address diagnostic challenges for older populations and highlight the diminished sensitivity of traditional symptoms with age, and the importance of biomarkers and imaging techniques tailored for older patients. Additionally, we review the efficacy and safety of pharmacological agents for ACS management in older people, emphasizing the need for a personalized and shared decision-making approach to treatment. This review also explores revascularization strategies, considering the implications of invasive procedures in older people, and weighing the potential benefits against the heightened procedural risks, particularly with surgical revascularization techniques. We explore the perioperative management of older patients experiencing myocardial infarction in the setting of noncardiac surgeries, including preoperative risk stratification and postoperative care considerations. Furthermore, we highlight the critical role of a multidisciplinary approach involving cardiologists, geriatricians, general and internal medicine physicians, primary care physicians, and allied health, to ensure a holistic care pathway in this patient cohort.
- 28 July 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (15) , 4416
Open AccessManagement of Acute Coronary Syndromes in Older People: Comprehensive Review and Multidisciplinary Practice-Based Recommendations
Managing health care for older adults aged 75 years and older can pose unique challenges stemming from age-related physiological differences and comorbidities, along with elevated risk of delirium, frailty, disability, and polypharmacy. This review is aimed at providing a comprehensive analysis of the management of acute coronary syndromes (ACS) in older patients, a demographic substantially underrepresented in major clinical trials. Because older patients often exhibit atypical ACS symptoms, a nuanced diagnostic and risk stratification approach is necessary. We aim to address diagnostic challenges for older populations and highlight the diminished sensitivity of traditional symptoms with age, and the importance of biomarkers and imaging techniques tailored for older patients. Additionally, we review the efficacy and safety of pharmacological agents for ACS management in older people, emphasizing the need for a personalized and shared decision-making approach to treatment. This review also explores revascularization strategies, considering the implications of invasive procedures in older people, and weighing the potential benefits against the heightened procedural risks, particularly with surgical revascularization techniques. We explore the perioperative management of older patients experiencing myocardial infarction in the setting of noncardiac surgeries, including preoperative risk stratification and postoperative care considerations. Furthermore, we highlight the critical role of a multidisciplinary approach involving cardiologists, geriatricians, general and internal medicine physicians, primary care physicians, and allied health, to ensure a holistic care pathway in this patient cohort.
- 1 July 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 17 (7) , e013739
Graft Patency and Clinical Outcomes in Patients With Radial Artery Grafts Previously Instrumented for Cardiac Catheterization
BACKGROUND: While transradial access is favored for cardiac catheterization, the radial artery (RA) is increasingly preferred for coronary artery bypass grafting. Whether the RA is suitable for use as a graft following instrumentation for transradial access remains uncertain. METHODS: Consecutive patients from 2015 to 2019 who underwent coronary artery bypass grafting using both the left and right RAs as grafts were included. Instrumented RAs underwent careful preoperative assessment for suitability. The clinical analysis was stratified by whether patients received an instrumented RA graft (instrumented versus noninstrumented groups). Eligible patients with both instrumented and noninstrumented RAs underwent computed tomography coronary angiography to evaluate graft patency. The primary outcome was a within-patient paired analysis of graft patency comparing instrumented to noninstrumented RA grafts. RESULTS: Of the 1123 patients who underwent coronary artery bypass grafting, 294 had both the left and right RAs used as grafts and were included. There were 126 and 168 patients in the instrumented and noninstrumented groups, respectively. Baseline characteristics and perioperative outcomes were comparable. The rate of major adverse cardiac events at 2 years following coronary artery bypass grafting was 2.4% in the instrumented group and 5.4% in the noninstrumented group (hazard ratio, 0.44 [95% CI, 0.12–1.61]; P =0.19). There were 50 patients included in the graft patency analysis. At a median follow-up of 4.3 (interquartile range, 3.7–4.5) years, 40/50 (80%) instrumented and 41/50 (82%) noninstrumented grafts were patent (odds ratio, 0.86 [95% CI, 0.29–2.52]; P >0.99). No significant differences were observed in the luminal diameter or cross-sectional area of the instrumented and noninstrumented RA grafts. CONCLUSIONS: There was no evidence found in this study that RA graft patency was affected by prior transradial access, and the use of an instrumented RA was not associated with worse outcomes in the exploratory clinical analysis. Although conduits must be carefully selected, prior transradial access should not be considered an absolute contraindication to the use of the RA as a bypass graft. REGISTRATION: URL: https://www.anzctr.org.au/ ; Unique identifier: ACTRN12621000257864.
- 1 July 2024
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 17 (7) , e013739
Graft Patency and Clinical Outcomes in Patients With Radial Artery Grafts Previously Instrumented for Cardiac Catheterization
BACKGROUND: While transradial access is favored for cardiac catheterization, the radial artery (RA) is increasingly preferred for coronary artery bypass grafting. Whether the RA is suitable for use as a graft following instrumentation for transradial access remains uncertain. METHODS: Consecutive patients from 2015 to 2019 who underwent coronary artery bypass grafting using both the left and right RAs as grafts were included. Instrumented RAs underwent careful preoperative assessment for suitability. The clinical analysis was stratified by whether patients received an instrumented RA graft (instrumented versus noninstrumented groups). Eligible patients with both instrumented and noninstrumented RAs underwent computed tomography coronary angiography to evaluate graft patency. The primary outcome was a within-patient paired analysis of graft patency comparing instrumented to noninstrumented RA grafts. RESULTS: Of the 1123 patients who underwent coronary artery bypass grafting, 294 had both the left and right RAs used as grafts and were included. There were 126 and 168 patients in the instrumented and noninstrumented groups, respectively. Baseline characteristics and perioperative outcomes were comparable. The rate of major adverse cardiac events at 2 years following coronary artery bypass grafting was 2.4% in the instrumented group and 5.4% in the noninstrumented group (hazard ratio, 0.44 [95% CI, 0.12–1.61]; P =0.19). There were 50 patients included in the graft patency analysis. At a median follow-up of 4.3 (interquartile range, 3.7–4.5) years, 40/50 (80%) instrumented and 41/50 (82%) noninstrumented grafts were patent (odds ratio, 0.86 [95% CI, 0.29–2.52]; P >0.99). No significant differences were observed in the luminal diameter or cross-sectional area of the instrumented and noninstrumented RA grafts. CONCLUSIONS: There was no evidence found in this study that RA graft patency was affected by prior transradial access, and the use of an instrumented RA was not associated with worse outcomes in the exploratory clinical analysis. Although conduits must be carefully selected, prior transradial access should not be considered an absolute contraindication to the use of the RA as a bypass graft. REGISTRATION: URL: https://www.anzctr.org.au/ ; Unique identifier: ACTRN12621000257864.
- 12 June 2024
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 33 (10) , 1404-1413
Ultrasound Guidance for Transradial Access in the Cardiac Catheterisation Laboratory: A Systematic Review of the Literature and Meta-Analysis
- 12 June 2024
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 33 (10) , 1404-1413
Ultrasound Guidance for Transradial Access in the Cardiac Catheterisation Laboratory: A Systematic Review of the Literature and Meta-Analysis
- 27 February 2023
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 16 (4) , 457-467
Characteristics of Radial Artery Coronary Bypass Graft Failure and Outcomes Following Subsequent Percutaneous Coronary Intervention
- 27 February 2023
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 16 (4) , 457-467
Characteristics of Radial Artery Coronary Bypass Graft Failure and Outcomes Following Subsequent Percutaneous Coronary Intervention
- 8 January 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 101 (2) , 233-242
Intravascular lithotripsy in the treatment of coronary artery calcification in a high‐risk real world population
Background: The DISRUPT‐CAD study series demonstrated feasibility and safety of intravascular lithotripsy (IVL) in selected patients, but applicability across a broad range of clinical scenarios remains unclear.Aims: This study aims to evaluate the procedural and clinical outcomes of IVL in a high‐risk real‐world cohort, compared to a regulatory approval cohort.Methods: Consecutive patients treated with IVL and percutaneous coronary intervention at our center from May 2016 to April 2020 were included. Comparison was made between those enrolled in the DISRUPT‐CAD series of studies to those with calcified lesions but an exclusion criteria.Results: Among 177 patients treated with IVL, 142 were excluded from regulatory trials due to acute coronary syndrome presentation (47.2%), left ventricular ejection fraction p = 0.019), and more treated ACC/AHA C lesions (56.3% vs. 37.1%, p = 0.042). Rates of device success (93.7% vs. 100.0%, p = 0.208), procedural success (96.5% vs. 100.0%, p = 0.585), and minimal lumen area gain (221.2 ± 93.7% vs. 198.6 ± 152.0%, p = 0.807) were similar in both groups. The DISRUPT‐CAD cohort had no in‐hospital mortality, 30‐day major adverse cardiac events (MACE), or 30‐day target vessel revascularization (TVR). The clinical cohort had an in‐hospital mortality of 4.2%, 30‐day MACE of 7.8%, and 30‐day TVR of 1.5%. There was no difference in 12‐month TVR (2.9% vs. 2.2%; p = 0.825). Twelve‐month MACE was higher in the clinical cohort (21.1% vs. 8.6%, p = 0.03).Conclusion: IVL use remains associated with high clinical efficacy, procedural success, and low complication rates in a real‐world population previously excluded from regulatory approving trials.
- 8 January 2023
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 101 (2) , 233-242
Intravascular lithotripsy in the treatment of coronary artery calcification in a high‐risk real world population
Background: The DISRUPT‐CAD study series demonstrated feasibility and safety of intravascular lithotripsy (IVL) in selected patients, but applicability across a broad range of clinical scenarios remains unclear.Aims: This study aims to evaluate the procedural and clinical outcomes of IVL in a high‐risk real‐world cohort, compared to a regulatory approval cohort.Methods: Consecutive patients treated with IVL and percutaneous coronary intervention at our center from May 2016 to April 2020 were included. Comparison was made between those enrolled in the DISRUPT‐CAD series of studies to those with calcified lesions but an exclusion criteria.Results: Among 177 patients treated with IVL, 142 were excluded from regulatory trials due to acute coronary syndrome presentation (47.2%), left ventricular ejection fraction p = 0.019), and more treated ACC/AHA C lesions (56.3% vs. 37.1%, p = 0.042). Rates of device success (93.7% vs. 100.0%, p = 0.208), procedural success (96.5% vs. 100.0%, p = 0.585), and minimal lumen area gain (221.2 ± 93.7% vs. 198.6 ± 152.0%, p = 0.807) were similar in both groups. The DISRUPT‐CAD cohort had no in‐hospital mortality, 30‐day major adverse cardiac events (MACE), or 30‐day target vessel revascularization (TVR). The clinical cohort had an in‐hospital mortality of 4.2%, 30‐day MACE of 7.8%, and 30‐day TVR of 1.5%. There was no difference in 12‐month TVR (2.9% vs. 2.2%; p = 0.825). Twelve‐month MACE was higher in the clinical cohort (21.1% vs. 8.6%, p = 0.03).Conclusion: IVL use remains associated with high clinical efficacy, procedural success, and low complication rates in a real‐world population previously excluded from regulatory approving trials.
- 28 October 2022
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 31 (12) , 1619-1629
Trends and Real-World Safety of Patients Undergoing Percutaneous Coronary Intervention for Symptomatic Stable Ischaemic Heart Disease in Australia
- 28 October 2022
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 31 (12) , 1619-1629
Trends and Real-World Safety of Patients Undergoing Percutaneous Coronary Intervention for Symptomatic Stable Ischaemic Heart Disease in Australia